Pharma Mar, S.A.

MCE PHM.MC

Pharma Mar, S.A. Gross Profit Margin for the year ending December 31, 2023: 93.92%

Pharma Mar, S.A. Gross Profit Margin is 93.92% for the year ending December 31, 2023, a 0.93% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Pharma Mar, S.A. Gross Profit Margin for the year ending December 31, 2022 was 93.05%, a 0.22% change year over year.
Pharma Mar, S.A. Gross Profit Margin for the year ending December 31, 2021 was 92.85%, a -2.18% change year over year.
Pharma Mar, S.A. Gross Profit Margin for the year ending December 31, 2020 was 94.92%, a 1.08% change year over year.
Pharma Mar, S.A. Gross Profit Margin for the year ending December 31, 2019 was 93.91%, a 20.58% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

MCE: PHM.MC

Pharma Mar, S.A.

CEO	Mr. Jose Maria Fernandez Sousa-Faro Ph.D.
IPO Date	Sept. 8, 2000
Location	Spain
Headquarters	Avenida de los Reyes, 1
Employees	509
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Key trends

Past 5 years